302 related articles for article (PubMed ID: 22037771)
1. Niacin: the evidence, clinical use, and future directions.
Villines TC; Kim AS; Gore RS; Taylor AJ
Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
4. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
5. The role of niacin in lipid-lowering treatment: are we aiming too high?
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2013; 19(17):3094-106. PubMed ID: 23317400
[TBL] [Abstract][Full Text] [Related]
6. Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin.
Tuteja S; Qu L; Vujkovic M; Dunbar RL; Chen J; DerOhannessian S; Rader DJ
J Am Heart Assoc; 2018 Oct; 7(19):e03488. PubMed ID: 30371334
[TBL] [Abstract][Full Text] [Related]
7. Niacin in cardiovascular disease: recent preclinical and clinical developments.
Digby JE; Ruparelia N; Choudhury RP
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):582-8. PubMed ID: 22207729
[TBL] [Abstract][Full Text] [Related]
8. Niacin as antidyslipidemic drug.
Julius U
Can J Physiol Pharmacol; 2015 Dec; 93(12):1043-54. PubMed ID: 26370906
[TBL] [Abstract][Full Text] [Related]
9. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
11. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Pandian A; Arora A; Sperling LS; Khan BV
Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
Schulz I
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
14. Effects of niacin on glucose control in patients with dyslipidemia.
Goldberg RB; Jacobson TA
Mayo Clin Proc; 2008 Apr; 83(4):470-8. PubMed ID: 18380993
[TBL] [Abstract][Full Text] [Related]
15. Optimal pharmacotherapy to combat the atherogenic lipid triad.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
[TBL] [Abstract][Full Text] [Related]
16. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
McKenney JM
Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
[TBL] [Abstract][Full Text] [Related]
18. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
Vosper H
Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
[TBL] [Abstract][Full Text] [Related]
19. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Vasc Health Risk Manag; 2007; 3(4):467-79. PubMed ID: 17969377
[TBL] [Abstract][Full Text] [Related]
20. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Robinson JG
Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
